Skip Navigation LinksHome > March 2012 - Volume 34 - Issue 2 > Priming of Hematopoietic Progenitor Cells by Plerixafor and...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31821c2cb8
Clinical and Laboratory Observations

Priming of Hematopoietic Progenitor Cells by Plerixafor and Filgrastim in Children With Previous Failure of Mobilization With Chemotherapy and/or Cytokine Treatment

Sevilla, Julián MD; Schiavello, Elisabetta MD; Madero, Luis MD; Pardeo, Manuela MD; Guggiari, Elena MD; Baragaño, Marta MD; Luksch, Roberto MD; Massimino, Maura MD

Collapse Box


Plerixafor has been recently approved by the European Medicines Agency for adult patients who have failed other mobilization strategies. Experience in children, however, is extremely limited. We describe the experience of the use of this drug in 8 children under a compassionate-use program in 3 Italian and 2 Spanish centers. Plerixafor was generally well tolerated; only 2 of 8 children reported adverse effects, and these were mild in intensity. Peripheral blood progenitor cell priming was improved with plerixafor in 6 of 8 patients. In the remaining 2 patients, the target CD34+ cell count was below the target of 2×106 cells/kg, although in these patients cell counts before collection were good enough for leukapheresis. Plerixafor, therefore seems to be safe and effective for peripheral blood progenitor cell mobilization in children. Adverse events were comparable with those described with filgrastim alone.

Copyright © 2012 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.